Observational studyClinical rheumatology2026
The presence of anti-Ro52/SSA antibodies may predict concomitant pulmonary hypertension and poorer survival in patients with connective tissue disease-associated interstitial lung disease.
Observational study in Clinical rheumatology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Clinical Significance of Echocardiographic Parameters in Patients with Pulmonary Hypertension Associated with Interstitial Lung Disease.Journal of cardiovascular development and disease · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectiveAlthough pulmonary hypertension (PH) and interstitial lung disease (ILD) are major contributors to mortality in patients with connective tissue disease (CTD), data on concomitant PH specifically in those with CTD-associated ILD (CTD-ILD) remain limited. We aimed to identify predictors for PH development in CTD-ILD patients, and assess their impact on survival in this population.
methodThis retrospective observational study included 224 patients with CTD-ILD, confirmed through multidisciplinary discussion, including patients with inflammatory myopathy-associated ILD (IIM-ILD, n = 88), systemic sclerosis-associated ILD (SSc-ILD, n = 57), rheumatoid arthritis-associated ILD (RA-ILD, n = 55), and primary Sjögren's syndrome-associated ILD (pSS-ILD, n = 24). PH was diagnosed using right heart catheterization (RHC) or, in patients unable to undergo RHC, by transthoracic echocardiography. Autoantibodies related to IIM and SSc were assessed using Euroimmun immunoblot assays.
resultsAmong CTD-ILD patients, 28 (12.5%) had concomitant PH: SSc-ILD (21.1%), IIM-ILD (13.6%), RA-ILD (5.5%), and pSS-ILD (4.2%). Multivariate regression analysis revealed CTD duration, exertional dyspnea, nonspecific interstitial pneumonitis in HRCT, ANA-speckled pattern, anti-Ro52/SSA positivity, and anti-fibrotic agents were significant predictors of concomitant PH in overall CTD-ILD patients (all p < 0.05), and only anti-Ro52/SSA positivity is still a significant predictor in SSc-ILD/IIM-ILD subtypes. Anti-Ro52/SSA antibody positivity could predict PH emergence with AUC 0.64, specificity 75.4%, accuracy 72.3%, and negative predictive value 91.3% in CTD-ILD patients. Furthermore, CTD-ILD patients with PH and anti-Ro52/SSA positivity had higher mortality rates and shorter survival than those without PH or these autoantibodies.
conclusionAnti-Ro52/SSA antibody positivity may serve as a promising predictor of PH development and poorer survival in patients with CTD-ILD. Key Points • Pulmonary hypertension (PH) was identified in 12.5% of patients with CTD-ILD, with the highest prevalence in systemic sclerosis-ILD and inflammatory myopathy-ILD. • Anti-Ro52/SSA antibody positivity was independently associated with concomitant PH in CTD-ILD and remained significant in the SSc-ILD/IIM-ILD subgroup. • PH and anti-Ro52/SSA positivity were each associated with worse survival in CTD-ILD, supporting a potential role for anti-Ro52/SSA in risk stratification.
Indexed as
Identifiers
42113392What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.